Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Articles|October 10, 2022
How Do You Nourish Your Mental Health?
Author(s)Psychiatric Times Editors
In honor of World Mental Health Day, tell us how you maintain your mental health for a chance to be featured in our Wellbeing Checkup video series.
Advertisement
October 10 is World Mental Health Day. Do you have a go-to method for nourishing your mental health? Psychiatric TimesTM wants to hear from you!
Contact us now to be featured in an upcoming episode of
If you would like to discuss your healthy habits in an upcoming episode of Wellbeing Checkup, write us at
Advertisement
Related to this article
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Interventional Options for TRD: ECT, TMS, and Esketamine
3
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
4
Defining Treatment-Resistant Depression In Adults
5